Humoral response to different SARS-CoV-2 vaccines in orthotopic liver transplant recipients

• DOI: 10.1016/j.vaccine.2022.08.027
• Publication Date: 2022-08-22T06:22:37Z
• Authors: Liz Toapanta-Yanc...; Erwin Chiquete; Esmeralda Ávila-Rojo; Silvia López-Yánez; Sonia Luna del Vi...; Sergio Rivera Monroy; Tomás López Gómez; Juan Bruno Andrés...; Denek Francisco B...; Carlos Alcaraz-Fu...; Magdalena García ...; José Luis López J...; Ernesto Márquez-G...; Mario Vilatobá; Rodrigo Cruz-Mart...; Paulina Carpintey...; Mariana Chávez-Villa; Ricardo Daniel Ro...; Daniel Torres-del...; Luis F. Uscanga-D...; Mario García-Alanis; Ramiro Tapia Sosa; Maximiliano Serví...; Raymundo David Va...; Ignacio García-Ju...
• Keywords: 2019-20 coronavirus outbreak; Sars virus; Betacoronavirus; Humoral immunity

The safety and efficacy data of the different types of available vaccines is still needed. The goal of the present analysis was to evaluate the humoral response to the COVID-19 vaccines in orthotopic liver transplant (OLT) recipients.Participants were included from February to September 2021. No prioritized vaccination roll call applied for OLT patients. Controls were otherwise healthy people. Blood samples were drawn after 15 days of the complete vaccine doses. The samples were analyzed according to the manufacturer's instructions using the Liaison XL platform from DiaSorin (DiaSorin S.p.A., Italy), and SARS-COV-2 IgG II Quant (Abbott Diagnostics, IL, USA).A total of 187 participants (133 OLT, 54 controls, median age: 60 years, 58.8% women) were included for the analysis; 74.3% had at least one comorbidity. The serologic response in OLT patients was lower than in controls (median 549 AU/mL vs. 3450 AU/mL, respectively; p = 0.001). A positive humoral response was found in 133 OLT individuals: 89.2% with BNT162b2 (Pfizer-BioNTech), 60% ChAdOx1 nCOV-19 (Oxford-AstraZeneca), 76.9% with CoronaVac (Sinovac, Life Sciences, China), 55.6% Ad5-nCov (Cansino, Biologics), 68.2% Gam-COVID-Vac (Sputnik V) and 100% with mRNA-1273. In controls the serological response was 100%, except for Cansino (75%). In a multivariable model, personal history of COVID-19 and BNT162b2 inoculation were associated with the serologic response, while the use of prednisone (vs. other immunosuppressants) reduced this response.The serologic response to COVID-19 vaccines in OLT patients is lower than in healthy controls. The BNT162b2 vaccine was associated with a higher serologic response.